BACKGROUND: Nearly 1 in 5 Americans will develop skin cancer, and as a result, survivors of skin cancer compose one of the largest groups of cancer survivors. Survivorship care plans (SCPs) are an important tool for improving patient outcomes and provide critical information to both survivors and health care professionals. Recent efforts have been made to expand SCP utilization; however, which patients currently receive SCPs is poorly understood. METHODS: This study used 596 individuals with a diagnosis of melanoma (n 5 391) or nonmelanoma skin cancer (n 5 205) who had used an Internet-based SCP tool from May 2010 to December 2016 to model the patient and provider characteristics that determine SCP utilization. RESULTS: Survivors were predominantly white (95.3%) and female (56.5%). Survivors who received a treatment summary were more likely to also receive an SCP. University and nonuniversity cancer centers used SCPs at a higher rate than other care settings. Survivors whose care was managed by a team rather than just an individual physician were also more likely to receive an SCP. Survivors older than 70 years at diagnosis were almost twice as likely to receive a plan as survivors who were diagnosed at a younger age. CONCLUSIONS: With a convenience sample of skin cancer survivors, it is possible to model factors that predict the receipt of SCPs. Important variables include the diagnosis age, treatment setting, physician type, and treatment-summary utilization. A closer examination of these variables identified several disparities in care-plan use and, therefore, opportunities to improve the distribution of SCPs. Further validation in additional cohorts of survivors is necessary to confirm these conclusions. Cancer 2018;124:183-91.
INTRODUCTION
Each year, there are more new cases of skin cancer than the next 5 most prevalent cancer types combined; nearly 20% of US residents will develop skin cancer at least once during their lifetime. 1 Fortunately, a majority of these cases are relatively benign basal cell carcinomas and are not even tracked on most cancer registries. 2 The incidence of melanoma has doubled in the past 25 years 3 ; however, the 5-year survival rate remains high at more than 90%. The high incidence and survival rates across skin cancer types combine to create a large population of skin cancer survivors.
Cancer survivorship begins at the time of diagnosis and continues throughout the patient's life. Survivorship care focuses on the physical, psychosocial, and economic issues that patients may experience as a result of normal aging and because of their cancer diagnosis and treatment. To address some of these issues, the Institute of Medicine recommends that all patients completing cancer treatment receive a survivorship care plan (SCP), which includes information about the treatments that a patient has received, possible late and long-term effects of treatment, recommendations for future checkups and cancer screenings, and ideas for improving overall health. 4 Previous work has demonstrated that survivors who receive SCPs report improved peace of mind and better patient-physician communication. 5 Good communication is especially important among skin cancer survivors because 5% of nonmelanoma skin cancer patients 6 and 30% of melanoma patients 7 will have at least 1 recurrence in their lifetime. Therefore, good physician communication and continued screening are paramount.
Despite the documented benefits of receiving an SCP, most healthcare centers do not consistently provide them to patients. 8 A study of 81 cancer programs in the United States found that SCP use was associated with geography, requests for information initiated by the patient, and cancer center membership in the National Cancer Institute's Community Cancer Centers Program. 9 However, little is known about what patient characteristics determine whether an individual patient will receive an SCP. Understanding which patients are currently receiving care plans will allow more targeted recommendations to improve care-plan utilization in underserved survivor populations. This study took advantage of a convenience sample of patients and physicians who used a free, Internet-based tool to create SCPs. In addition to requesting information about treatments and side effects, the tool also collects demographic information and information about the treatment setting and the physician type. We used this information in combination with supervised machine learning to model factors that influenced whether a skin cancer patient would receive an SCP to identify opportunities to improve the dissemination of survivorship information to this survivor population.
MATERIALS AND METHODS

SCPs
OncoLink, a program at the University of Pennsylvania, developed and maintains a free, publicly available online SCP generator (https://www.oncolink.org/). 10 The interactive online survey enables physicians, patients, or their family members to input demographic data, information on the cancer type and status as well as treatments, and, in the patient version, information on late and long-term effects of treatments. An in-depth explanation of the questions and information contained in the OncoLink resource has been previously reported. 10 On the basis of the responses to these questions, the patient then receives personalized, evidence-based health care recommendations for future care, potential late and long-term effects and other general wellness suggestions.
Data Collection and Analysis
Patients and physicians who used OncoLink from May 2010 to December 2016 and indicated a diagnosis of skin cancer were included in this analysis. Only fully completed surveys were used in this analysis. Institutional review board approval was obtained before the collection of patient data and the subsequent analysis.
Random forest, a supervised machine learning approach, was used to model the interaction between demographic factors such as sex and race as well as treatmentassociated factors such as the cancer type, physician type, and care setting on whether a patient had received an SCP. 11 For the outcome variable (whether a patient had received an SCP), in the patient version of the survey, participants were asked whether they had previously been provided a survivorship care plan, and they were categorized as yes or no on the basis of their responses. In the physician version of the survey, where physicians entered the information on behalf of patients to provide them with the resulting care plan, all respondents were considered yes. Each model was constructed with two-thirds of the total responses (randomly selected) and was validated with the remaining onethird to provide an estimate of its accuracy. The analysis was performed with the randomForest R package with the variables set to 1000 trees per run, with a node size of 2, and with mtry set to the number of variables in the model.
To understand how the demographic and treatment-associated factors were related to one another and to whether the patient received an SCP, we constructed a variable interaction network with the algorithm for the reconstruction of accurate cellular networks (ARA-CNE) analysis method from the minet R package with Spearman correlations. 12 Using the resulting mutual information matrix, which showed the strength of the association between every combination of 2 variables included in the model, we created an undirected graph of the interaction between our variables, with the connecting lines weighted on the strength of the association between variables. To validate results from the random forest and ARACNE analyses, we performed a univariate analysis with a chi-square test.
For geographical analyses, the state indicated by the respondent was binned into the Northeast, South, Midwest, or West category according to the geographic designations used by the US Census Bureau. Data were visualized with the maps and ggplot2 packages in R.
All data analysis was performed with the R language and environment for statistical computing and graphics (https://www.r-project.org); all P values were from a chisquare test.
RESULTS
Demographics
SCPs were created for a total of 596 survivors: 391 with melanoma and 205 with nonmelanoma skin cancer. Overall, respondents were more likely to be female (56.5%) and white (95.3%). Melanoma survivors were significantly younger on average at diagnosis in comparison with nonmelanoma skin cancer survivors with mean diagnosis ages of 52 and 67 years, respectively. Melanoma patients were more likely to report living in the suburbs (49.6%), whereas most nonmelanoma skin patients were from urban areas (51.2%). Although the online care-plan generator was developed and maintained at the University of Pennsylvania, patients throughout the country used the resource, with only 34.5% of melanoma patients and 14.6% of nonmelanoma skin cancer patients hailing from the Northeast. Melanoma patients were more likely than nonmelanoma skin cancer patients to be treated at a university-based cancer center (37.3% vs 9.3%) and receive a treatment summary (24.3% vs 8.3%). Nearly half of both patient populations reported receiving an SCP. Full demographic data for the survivors included in this study can be found in Table 1 .
Supervised Machine Learning to Identify Factors That Affect Whether a Patient Receives an SCP
Significant differences were observed in demographic characteristics between melanoma and nonmelanoma survivors, but roughly equal numbers of each patient group reported receiving an SCP (Table 1) . Therefore, to better understand what patient and provider characteristics influenced whether a patient received an SCP, we used random forest, a machine learning technique, to identify which demographic factors from Table 1 were most relevant in determining whether a patient would receive an SCP. The goal of this analysis was to create a decision tree identifying which variables from Table 1 strongly influence whether a given skin cancer patient will receive an SCP. The random forest model was created with twothirds of the survivors and was validated with the remaining one-third to guard against bias. The overall out-of-bag error rate for the model was 33.56%, and this meant that the model was able to identify correctly whether a given survivor received an SCP two-thirds of the time. For each factor, a variable importance score was determined (Fig.  1A) ; this measured the contribution of the variable to the error rate of the model. Higher scores meant that the variable was more important to the accuracy of the model and more strongly influenced the likelihood that a patient would receive an SCP. From this analysis, the 5 most important variables for determining whether a survivor received an SCP were as follows: the receipt of a treatment summary, the type of physician managing the survivor's health care, the type of treatment setting, the survivor's age at diagnosis, and the survivor's region of the country.
Modeling the factors that determine whether a patient receives an SCP with the random forest technique identifies which variables are important in predicting whether a survivor receives an SCP. However, many of these variables, such as what type of physician is managing the patient's care and where the patient is receiving treatment, are interrelated. To visualize the relations between these variables, we used an ARACNE network analysis to look at the strength of the relation between each variable and every other variable included in the model. The resulting network (Fig. 1B) displays the strongest relations in the model; the thickness of the line connecting any 2 variables represents the strength of the relation between those 2 variables. Variables directly related to whether a patient received an SCP included the following: the type of physician who managed the patient's health care, the place where the patient received treatment, the patient's diagnosis age, and the receipt of a treatment summary. Indirect variables were related to survivorship care through one of the direct variables or through other indirect variables. All 4 direct interaction variables were also among the top 5 by variable importance score from the random forest analysis (Fig. 1A) , and this further confirmed their importance as the key factors in determining whether a patient receives an SCP.
Diagnosis Age Influences Whether a Patient Receives an SCP
One concern with a convenience sample is that participants are not representative of the general patient population, so any downstream analyses such as predictive modeling are skewed by bias. However, our survivor population recapitulated several important characteristics of the broader skin cancer patient population. Looking at the diagnosis age of survivors with a diagnosis of melanoma ( Fig. 2A) , we can see that females showed a bimodal distribution, whereas males had a single peak later in life; this is consistent with larger clinical studies that have found a second peak incidence of melanoma in women younger than 40 years. 13 In addition, the diagnosis age for melanoma survivors of both sexes was significantly younger than that for nonmelanoma skin cancer survivors ( Fig.  2A) , this is consistent with previous reports of a high diagnosis age for nonmelanoma skin cancer in populationlevel studies. 14 In addition to being an important way of comparing our survivors with the larger survivor population, the diagnosis age also had one of the highest importance scores by the random forest analysis and had a direct interaction with whether a survivor was offered an SCP by the ARACNE analysis (Fig. 1 ). Patients were grouped into bins by age, and we evaluated the proportion of patients in each age group who received an SCP (Fig. 2B) . Patients younger than 35 years and patients between 35 and 70 years at diagnosis received care plans at similar frequencies, with approximately 40% of each group reporting the receipt of an SCP. Surprisingly, more than 70% of the patients who were older than 70 years at the time of diagnosis received a care plan; this rate was significantly higher than the rates for the other 2 age groups (P 5 1.233 10 -8 ). These survivors older than 70 years were also more likely to have nonmelanoma skin cancers (67%) versus melanoma (33%); this was a reversal of the percentage of survivors with each cancer diagnosis in the overall study population. This finding suggests that younger survivors are less likely to receive survivorship information, highlighting an important underserved patient population.
Physician Type and Cancer Diagnosis Influence the Likelihood of Receiving an SCP
One of the most important variables identified in the random forest analysis that affected whether a given survivor received an SCP was the type of physician who managed their care ("managing health care" in Fig. 1A) . Unsurprisingly, there were differences between melanoma and nonmelanoma skin cancer survivors in the types of physicians treating them (Table 1) . There were also different patterns of care-plan usage between physician types. Patients treated by the combination of an oncologist and a primary care physician/internist were almost twice as likely to receive an SCP (69.6%) as patients treated by either an oncologist (35.6%) or a primary care provider/internist (40%) alone (P 5 3.62 3 10 -14 ; Fig. 3A) . Survivors who indicated other and were seeing providers such as dermatologists for care were less likely to receive a care plan, with only 21.4% of these patients reporting that they had received an SCP.
However, within each physician type, there were also significant differences in care-plan utilization depending on the survivor's cancer type (P 5 6.76 3 10 -3 ; Fig. 3B ). Nonmelanoma skin cancer patients were almost twice as likely as melanoma patients to receive a care plan from a primary care physician (58% vs 31%). Melanoma patients received care plans when they were treated by a combination of physicians at a slightly higher rate (75% vs 61%). These trends give some insight into how different physician types view the need for survivorship materials for patients with different cancer diagnoses. 
Treatment Setting and Cancer Diagnoses Influence the Likelihood of Receiving an SCP
Roughly half of all survivors with each diagnosis received an SCP (Table 1) . However, melanoma patients were more than 4 times as likely as nonmelanoma skin survivors to receive care at a university-based cancer center (37.3% vs 9.3%), whereas nonmelanoma skin cancer patients were overwhelmingly treated at non-universitybased hospitals (54.6% vs 29.7%). Where the survivors received care also significantly affected their likelihood of receiving an SCP. Patients who were seen at a nonuniversity-affiliated hospital or a university-based cancer center were almost twice as likely to receive an SCP as patients who were seen in a private physician's office (P 5 7.60 3 10 -5
; Fig. 4A ). Interestingly, patients seen at a combination of these treatment settings were the least likely to report receiving an SCP.
The type of skin cancer influenced not only where a survivor received treatment but also how likely the survivor was to receive an SCP in each treatment setting (P 5 4.66 3 10 -4 ; Fig. 4B ). Melanoma patients were twice as likely as nonmelanoma patients to receive an SCP when they were treated at a university-based cancer center. However, this trend was reversed in private physician offices, where nonmelanoma patients were much more likely to receive an SCP. Rates of SCP utilization across cancer types were roughly equal for patients treated at nonuniversity hospitals and for patients treated at a combination of locations. This disparity shows that although physicians from settings ranging from large university cancer centers to private offices are aware of SCPs, they choose to use them in very different ways.
Regional Differences in Treatment Settings and Treatment-Summary Utilization
The final direct interaction variable from the ARACNE analysis was also the strongest. Whether a patient received a treatment summary directly correlated with whether they also received an SCP. More than two-thirds of the patients who received a treatment summary also reported receiving an SCP (Fig. 5A) . Patients who did not receive a treatment summary or were unsure were significantly less likely to report receiving a care plan (P 5 4.59 3 10 -5 ); they reported receiving SCPs 43.2% and 50% of the time, respectively.
Although the geographic region did not affect whether a patient received a care plan, there were significant regional variations in treatment-summary utilization. Of the 596 survivors included in this study, approximately 28% came from the Northeast, South, and West, whereas only 14.5% came from the Midwest (top of Fig.   5B ). Although the utilization of this online survivorship resource varied by geographic region, there was also significant regional variation in the utilization of treatment summaries (P 5 7.03 3 10 -10 ). Nearly 40% of the patients in the Northeast received a treatment summary, whereas patients in the Midwest, West, and South received treatment summaries only 10% to 20% of the time (bottom of Fig. 5B ). This identifies an important opportunity for improving other aspects of survivorship care throughout the country.
DISCUSSION
SCPs play an important role in improving patient knowledge about treatment, increase survivor-physician communication, and decrease psychological distress after treatment. [15] [16] [17] Despite these benefits, a minority of treatment settings use SCPs, and those that do tend to use them only for certain cancer types. 18 This study demonstrates the feasibility of using a convenience sample of survivors to model demographic and treatment-related factors that influence whether a skin cancer survivor receives an SCP. Although the survivors in this study frequently reported either no or very mild long-term physical side effects such as lymphedema or tingling associated with lymph node biopsy or lymphadenectomy, they were still at risk for psychosocial effects of their diagnosis and treatment. 19 Because the study used a convenience sample of survivors, care should be taken in expanding the conclusions to other groups of cancer survivors. However, the study population recaptured several of the demographic characteristics of the larger skin cancer patient population, including the difference in the diagnosis age between melanoma and nonmelanoma skin cancer survivors and the bimodal distribution in the diagnosis age of female melanoma survivors. The statistical modeling of the factors that influenced whether a patient received an SCP also identified several important opportunities to improve care-plan dissemination. Survivors older than 70 years were significantly more likely to receive a care plan. However, because of the high recurrence rate of melanoma, 7 the younger melanoma survivors would have also benefited from having access to the resources included in an SCP, but they received one almost half as frequently as the survivors older than 70 years.
The statistical modeling also identified the type of physician treating the survivor and the clinical setting in which the survivor received treatment as important factors influencing whether the survivor received an SCP. Patients treated by the combination of a primary care physician/internist, an oncologist, and/or another physician were almost twice as likely to receive a care plan as patients treated by only one of these providers. This is encouraging because one of the goals of survivorship information is to allow survivors to take information related to their cancer care back to their primary physician. Whether this increase in use for patients treated by multiple physicians is a conscious decision to improve communication between providers or is a byproduct of patients who are more proactive in seeking care also being more proactive in requesting survivorship information is unclear.
Although being treated by multiple types of physicians improved a survivor's chance of receiving a care plan, being treated at multiple locations significantly decreased a patient's chances of receiving a care plan. This could be due to a diffusion of responsibility, with both providers assuming that the other would provide the information. However, this is an important patient group to focus on because communication is paramount when a patient is seeing multiple providers, especially across different health systems; under these circumstances, complete patient records may not be easily shared and accessed. In addition, different care settings used care plans at different rates according to the cancer type. This suggests that different treatment settings have different approaches to distributing survivorship care, and it highlights the need for a more standardized approach to SCP use.
There was also significant regional variation in the utilization of treatment summaries, the most predictive variable for whether a patient received an SCP. This is consistent with previous research, which has shown that these 2 documents are frequently given to survivors at the same time. 18 Two-thirds of the survivors who received a treatment summary also received a care plan, and patients in the Northeast were twice as likely to get a treatment summary as patients from other regions of the country. Although the possible reasons for this disparity are numerous, this finding highlights an important opportunity for expanding the usage of both treatment summaries and SCPs throughout the country.
On the basis of the survivors and physicians who used OncoLink, there were striking differences in patterns of care-plan use in the clinic among skin cancer survivors without any clear differences in survivorship needs between patients who did receive a plan and patients who did not receive one. With SCP use increasingly being tied to accreditation by groups such as the National Cancer Institute and the American College of Surgeons, it is critical to identify these underserved populations and provide them with care plans both to maintain accreditation and to address an unmet health need among survivors. Using statistical modeling to identify characteristics influencing the utilization of SCPs among skin cancer patients, we identified several important factors that predict whether a patient will receive an SCP. Our models suggest that whether a patient receives a treatment summary, the type of physician managing the patient's health care, the treatment setting, the patient's age at diagnosis, and the region of the country are all important in determining whether the patient receives an SCP. Univariate validation of each of these factors has identified several opportunities for improving the utilization of SCPs among skin cancer patients. These include targeting the plans to younger patients and patients who are seen in multiple treatment settings. Further research is necessary to validate these findings in other groups of skin cancer survivors and to test these findings for other cancer types, but they raise important issues about how survivorship care is used and highlight several opportunities for improving survivorship care.
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